Are confined to an in vitro Huh-7 P. berghei model and the in vivo relevance of these findings remains elusive. In vivo characterization is hampered by the extremely low number of replicating parasites. Similarly, P. yoelii and P. MedChemExpress Fexaramine Fevipiprant web falciparum replicating Dp52 p36 parasites are extremely rare and at present their mechanism of breakthrough remains unclear. Nevertheless, once confirmed in P. falciparum, our findings may have implications forCytosolic Dp52 p36 P. berghei Lack Apparent PVMTable 1. Dp52 p36 merozoites are capable of inducing a blood-stage infection.Experiment no.No. Asexual positive/No.injected (mean d pre-patency)Dp52 p1 2 4/4 (660 days) 5/5 (5.860.4 days)WT 2/2 (360 days) 3/3 (260 days)Huh-7 cells were infected with Dp52 p36 and WT parasites and cultured for 65 hours. After 65 hours, culture supernatant containing merozoites was collected and injected i.v in C57BL/6 23727046 mice. Regular Giemsa staining was performed in all groups, 2?4 days post i.v injection in mice, to control for asexual parasites. doi:10.1371/journal.pone.0050772.tthe development of a genetically attenuated malaria vaccine. Based on protective efficacy conferred in mice and apparent full arrest in P. yoelii and P. falciparum models, genetically attenuated Dp52 p36 parasites have been considered eligible for clinical development as an attenuated sporozoite vaccine [7]. Given the break-through infections, our data suggest that for a sufficiently attenuated malaria vaccine, multiple genes need to be targeted. Such genes could not only include genes involved in the formation of the PVM, but preferably other Plasmodium gene targets with independent functions for liver stage development.(PBANKA_030600) on chromosome 3 (i.e. RMgm-29; http:// pberghei.eu/index.php?rmgm = 29). Hybridization with the 39UTR dhfr/ts probe recognizes the integrated construct on chromosome 9, the reporter GFP-Luccon construct on chromosome 3, andthe endogenous dhfr/ts gene located on chromosome 7. (TIF)Table S1 Quantitative analysis of replicating intranuclear and cytosolic wildtype and mutant parasites. a Average number of replicating liver stage parasites per coverslip. A total of 3 coverslips was counted per timepoint per parasite. (DOC)Supporting InformationFigure S1 Late liver stage intracytosolar Dp52 p36p parasites have an irregular shape. Four representative images of Dp52 p36p P. berghei parasites in culture 48 hours post invasion in Huh-7 cells. Msp-1 expression is depicted in red, DAPI in blue (Bar = 10 mm). (TIF) Figure S2 Confirmation of Dp52+p36 and wildtype genotype after merosome injection assay. A) Diagnostic PCR for confirmation of correct disruption of p52 and p36 in mutant Dp52+p36 (1409cl1). SM: selectable marker (primers 4501/4502; 1093bp); 59-integration event (primers L1389/L313; 1050bp); ORF (primers L775/L121; 1029bp). B) Sequence of the primers used. C) Southern analysis of pulse field gel (PFG)-separated chromosomes of mutant Dp52+p36. Mutant Dp52+p36 has been generated in the reference P. berghei ANKA line PbGFP-Luccon which has a gfpluciferase gene integrated into the silent 230p locusAcknowledgmentsWe are grateful to Professor Kai Matuschewski for providing the anti-UIS4 antibody. Moreover, we would like to thank Takeshi Annoura for confirmation of Dp52+p36 and wildtype genotype after the merosome injection assay. Additionally, we would like to thank Claudia Lagarde for the technical assistance with the P. berghei infections, Jolanda Klaassen, Laura Pelser-Posth.Are confined to an in vitro Huh-7 P. berghei model and the in vivo relevance of these findings remains elusive. In vivo characterization is hampered by the extremely low number of replicating parasites. Similarly, P. yoelii and P. falciparum replicating Dp52 p36 parasites are extremely rare and at present their mechanism of breakthrough remains unclear. Nevertheless, once confirmed in P. falciparum, our findings may have implications forCytosolic Dp52 p36 P. berghei Lack Apparent PVMTable 1. Dp52 p36 merozoites are capable of inducing a blood-stage infection.Experiment no.No. Asexual positive/No.injected (mean d pre-patency)Dp52 p1 2 4/4 (660 days) 5/5 (5.860.4 days)WT 2/2 (360 days) 3/3 (260 days)Huh-7 cells were infected with Dp52 p36 and WT parasites and cultured for 65 hours. After 65 hours, culture supernatant containing merozoites was collected and injected i.v in C57BL/6 23727046 mice. Regular Giemsa staining was performed in all groups, 2?4 days post i.v injection in mice, to control for asexual parasites. doi:10.1371/journal.pone.0050772.tthe development of a genetically attenuated malaria vaccine. Based on protective efficacy conferred in mice and apparent full arrest in P. yoelii and P. falciparum models, genetically attenuated Dp52 p36 parasites have been considered eligible for clinical development as an attenuated sporozoite vaccine [7]. Given the break-through infections, our data suggest that for a sufficiently attenuated malaria vaccine, multiple genes need to be targeted. Such genes could not only include genes involved in the formation of the PVM, but preferably other Plasmodium gene targets with independent functions for liver stage development.(PBANKA_030600) on chromosome 3 (i.e. RMgm-29; http:// pberghei.eu/index.php?rmgm = 29). Hybridization with the 39UTR dhfr/ts probe recognizes the integrated construct on chromosome 9, the reporter GFP-Luccon construct on chromosome 3, andthe endogenous dhfr/ts gene located on chromosome 7. (TIF)Table S1 Quantitative analysis of replicating intranuclear and cytosolic wildtype and mutant parasites. a Average number of replicating liver stage parasites per coverslip. A total of 3 coverslips was counted per timepoint per parasite. (DOC)Supporting InformationFigure S1 Late liver stage intracytosolar Dp52 p36p parasites have an irregular shape. Four representative images of Dp52 p36p P. berghei parasites in culture 48 hours post invasion in Huh-7 cells. Msp-1 expression is depicted in red, DAPI in blue (Bar = 10 mm). (TIF) Figure S2 Confirmation of Dp52+p36 and wildtype genotype after merosome injection assay. A) Diagnostic PCR for confirmation of correct disruption of p52 and p36 in mutant Dp52+p36 (1409cl1). SM: selectable marker (primers 4501/4502; 1093bp); 59-integration event (primers L1389/L313; 1050bp); ORF (primers L775/L121; 1029bp). B) Sequence of the primers used. C) Southern analysis of pulse field gel (PFG)-separated chromosomes of mutant Dp52+p36. Mutant Dp52+p36 has been generated in the reference P. berghei ANKA line PbGFP-Luccon which has a gfpluciferase gene integrated into the silent 230p locusAcknowledgmentsWe are grateful to Professor Kai Matuschewski for providing the anti-UIS4 antibody. Moreover, we would like to thank Takeshi Annoura for confirmation of Dp52+p36 and wildtype genotype after the merosome injection assay. Additionally, we would like to thank Claudia Lagarde for the technical assistance with the P. berghei infections, Jolanda Klaassen, Laura Pelser-Posth.
